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Abstract
Background: In 2008, researchers reported that Timothy Brown (the ‘Berlin Patient’), a man with HIV infection and
leukemia, received a stem-cell transplant that removed HIV from his body as far as can be detected. In 2013, an
infant born with HIV infection received anti-retroviral treatment shortly after birth, but was then lost to the health
care system for the next six months. When tested for HIV upon return, the child (the ‘Mississippi Baby’) had no
detectable viral load despite cessation of treatment. These remarkable clinical developments have helped
reinvigorate the field of ‘HIV cure’ research.
Discussion: Although this research field is largely in a pre-clinical phase, talk about curing HIV has become a regular
feature in the global mass media. This paper explores the language of HIV cure from philosophical, ethical and
historical perspectives. Examination of currently influential definitions of ‘functional’ and ‘sterilizing’ HIV cure reveal
that these conceptualizations are more complicated than they seem. Cure is often understood in narrowly biomedical
terms in isolation from the social and psychological dimensions of illness. Contemporary notions of HIV cure also inherit
some of the epistemic problems traditionally associated with cures for other health conditions, such as cancer. Efforts
to gain greater conceptual clarity about cure lead to the normative question of how ‘HIV cure research’ ought to be
talked about.
Summary: We argue that attention to basic concepts ethically matter in this context, and identify advantages as well
as potential pitfalls of how different HIV/AIDS stakeholders may make use of the concept of cure. While concepts other
than cure (such as remission) may be appropriate in clinical contexts, use of the word cure may be justified for other
important purposes in the struggle against HIV/AIDS.
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Mankind is extremely fond of every thing that
promises a sudden or miraculous cure.
William Buchan
Domestic Medicine: Or a Treatise on the Prevention
and Cure of Diseases by Regime and Simple Medicines
(1871).
Background
The rise of HIV cure language
The incurability of HIV is an important aspect of its
social history. At the start of the epidemic, HIV was the
plague of gay men and junkies, frighteningly stigma-
tized behaviors, and socially problematic modes of
transmissibility. People with HIV had observable phys-
ical wasting and co-infections, and there were no ef-
fective treatments. Almost every person infected with
the virus developed AIDS and died. When and where
antiretroviral therapy (ART) has become available, pol-
icies, public perceptions, and personal experiences
have largely shifted as HIV is viewed less as a death
sentence, and more as a treatable, chronic condition.
Another salient new shift may be on the horizon. A
number of recent developments have, in different
ways, provided hope that HIV could be controlled
more comprehensively than thought possible in the
past:
 Bone marrow transplantation. Timothy Brown
received a bone marrow transplant using cells from
a donor with a rare genetic mutation that confers
resistance to HIV infection. Twenty months after
the procedure, researchers reported they could find
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no trace of HIV in the recipient’s bone marrow,
blood or other organ tissues [1]. Three patients in
Boston that underwent a marrow transplantation
procedure – albeit without the genetic mutation that
confers resistance – initially seemed to attain similar
results, but subsequently experienced relapse [2].
 Initiation of ART in acute infection: adults. The
French National Agency of AIDS Research (ANRS)
collected data on HIV-infected adults in France who
initiated ART early after HIV infection. A recent
report described the medical course of 14 patients
(the ‘Visconti cohort’) who started ART within ten
weeks of infection, and were on treatment for an
average of 3 years. After stopping treatment, the
majority had undetectable viral loads for an average
of 7.5 years [3]. Researchers estimated that the
probability of maintaining viral control at 24 months
after discontinuing treatment was only 15%, but the
cohort may hold important clues about a possible
cure for HIV.
 Initiation of ART in acute infection: infants. An
infant diagnosed with HIV infection (the Mississippi
Baby’) at 30 hours after birth received aggressive
ART until 18 months of age. The infant was then
lost to the healthcare system for the next 6 months.
When tested for HIV upon return, the child had no
detectable viral load despite cessation of treatment
[4]. Unfortunately, after two medication-free years
HIV was detected in the child’s blood and antiretroviral
therapy was initiated [5]. A second infant treated early
with ART (the ‘Long Beach Baby’) achieved similar
results, but with an important difference: the child
is still on ART [6]. In Canada, in the light of the
Mississippi Baby case, researchers identified a
cohort of HIV-infected infants that had been started
on aggressive ART shortly after birth [7]. Treatment
of one of the infants was interrupted after 3 years
and 3 months, but unfortunately after two weeks
the child’s viral load increased dramatically and
ART was resumed [8].
How were these developments described? In the scien-
tific literature, the ‘Berlin Patient’ was described as a case
of ‘long-term control of HIV’ (Hutter G, Nowak D,
Mossner M, et. al. [1]). The article reporting the
‘Visconti cohort’ in France similarly described the pa-
tients’ condition in terms of ‘long-term immunovirolo-
gic control’ (Saez-Cirion A, Bacchus C, Hocqueloux L
et. al. [9]). In the New England Journal of Medicine,
the ‘Mississippi Baby’ case was reported in terms of
‘functional cure’ and ‘absence of detectable viremia’
(Persaud D, Gay H, Ziemniak C, et. al. [10]). Press reports,
however, overwhelmingly chose to describe these same
cases in terms of actual or potential HIV cure.
What does cure mean? Sterilizing and functional cures
What does ‘cure’ mean in HIV cure research? The scien-
tific HIV cure literature makes regular reference to dif-
ferent kinds of cures, and definitions have been offered.
The Food and Drug Administration (FDA) broadly de-
fines HIV cure research as an investigation evaluating
therapeutic interventions that would control or elimin-
ate HIV infection to the point where no treatment
would be needed to maintain health [11]. According to
the International AIDS Society (IAS), a sterilizing HIV
cure means: the elimination of all HIV-infected cells; a
functional HIV cure means the life-long control of virus
in the absence of ART, without achieving complete
eradication of HIV. More specifically, the IAS sees the
achievement of functional cure as a list of biomedical
indices: undetectable viral load; no CD4 loss; lack of dis-
ease progression (and hence, no need for ART), and lack
of HIV transmission risk [12]. HIV-positive patients fit-
ting this description – lifelong – after a curative inter-
vention would be functionally cureda. In short, HIV cure
research worthy of the name, independently of approach
(ART initiation during acute infection, stem cell trans-
plantation, gene therapy, ART intensification …) ultim-
ately aims to contribute to a future sterilizing or
functional cure. If these are the final goals of HIV cure
research, the understanding of basic concepts such as
sterilizing and functional cure should be as clear and un-
problematic as possible.
In briefly exploring these notions, we will make four
related claims: (1) definitions of sterilizing and func-
tional cure will have to be carefully distinguished from
the meanings given to ‘cure’ in everyday life as well as
related medical notions, such as remission; (2) cure as
understood in contemporary HIV cure literature belongs
firmly in what is called the ‘biomedical model’. Given
that this model has sometimes been criticized as reduc-
tive and inadequate in understanding disease (including
HIV), the advantages and pitfalls of conceptualizing HIV
cure from a purely biomedical perspective must be crit-
ically evaluated; (3) the distinction between sterilizing
and functional cure is part of a larger and longstanding
distinction (and tension) between what we will call abso-
lute and modern conceptions of cure, particularly con-
spicuous in the context of cancer; (4) contemporary
notions of HIV cure inherit some of the epistemic prob-
lems traditionally associated with cures for other health
conditions. These four claims support the broader point
that HIV cure concepts are works in progress, and raise
a normative question: given the conceptual uncertain-
ties, how should HIV research developments be talked
about? Many cancer clinicians still shy away from talking
about ‘cure’, even with cancers deemed curable [13].
Should we similarly avoid the ‘C word’ (i.e. cure) in the
HIV context, and if so, why and when?
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Discussion
The concept of HIV cure
The meanings of the commonsense notion of cure
The word ‘cure’ entered the English language in the 14th
Century, from the Latin curare (‘to take care of ’). Ac-
cording to the Merriam-Webster Medical Dictionary,
‘cure’ can mean:
1 recovery from a disease (‘his cure was complete’);
also: remission of signs or symptoms of a disease
especially during a prolonged period of observation
(‘a clinical cure’; ‘5-year cure of cancer’).
2 a drug, treatment, regimen, or other agency that
cures a disease (‘quinine is a cure for malaria’).
3 a course or period of treatment; especially one
designed to interrupt an addiction or compulsive
habit or to improve general health (‘take a cure for
alcoholism’; ‘an annual cure at a spa’).
The difference between an intervention as a cure and being
cured
One can distinguish here between cure conceived as an
intervention (‘drug, treatment, regime or other agency’;
‘course of treatment’) and cure as a physical state of
being in a person brought about by that intervention
(‘recovery’, ‘remission’). The proffered IAS and FDA defi-
nitions of sterilizing and functional cure are more state
of being definitions than intervention definitions. This
may be due to current uncertainty as to what approach,
if any single one, will enact a cure in the ‘state of being’
sense. This distinction may be valuable in the context of
research: it might help research participants avoid ‘fet-
ishizing’ particular interventions as offering salvation
from HIV by drawing attention to the desired future
state of being cured.
HIV cure and the biomedical model
In 1977, Engel argued that the ‘biomedical model of
disease’ was descriptively inaccurate and had negative
consequences for the clinician-patient encounter [14].
By the ‘biomedical model of disease’, he meant the view
that diseases are a derangement of underlying physical
mechanisms and therefore can only be properly under-
stood and managed at a physical (biological, virological,
immunological, genetic) level. Engel argued instead that
diseases – their classification, presentation, prevalence,
distribution and so on – are strongly shaped by social,
cultural and psychological forces. In addition, he argued
that ‘de-socializing’ disease could lead to inferior patient
care, in the form of (for example) physicians discounting
patient narratives of disease and relying too heavily on
batteries of laboratory tests. Others have made a similar
case in regard to mental health [9]. Engel believed that a
broader, what he called a ‘biopsychosocial’ model of
disease, would be more faithful to the phenomena and
more supportive of a holistic approach to patient care.
Since Engel’s writing, HIV has become a prime example of
a serious infectious disease being increasingly approached
by a broad, multidisciplinary ‘biopsychosocial’ model.
HIV cure definitions, however, are currently locked in
the old biomedical framework. Sterilizing and functional
definitions of HIV cure are all about physical states in
the body. What would a biopsychosocial – patient-
centered rather than disease-centered – conception of
HIV cure involve? Would this involve changing the IAS/
FDA definitions of HIV cure? Does their focus on phys-
ical states of the body render them inadequate, as Engel
might argue? At least two options seem open: expand
the notion of cure to incorporate social and psycho-
logical components of being cured, or reserve the con-
cept of ‘cure’ for biological phenomena while embedding
that construct in a larger biopsychosocial context. In re-
gard to the latter, there are interesting questions about
the relationship between cure and the related concept of
healing: patients may be cured but not (yet) healed. On
the physical level, the process of being cured of HIV
may increase risks for other conditions, such as cancer
or cardiovascular disease [10]. For example, a small
population of people who are infected with HIV are able
to control infection without medicines, such that their
viral load is not detectable by standard tests. Although
these so called “elite controllers” typically meet all cri-
teria for the definition of functional cure, they are
known to be at greater risk for chronic diseases than
those without HIV infection. In addition, being cured of
HIV biologically may be compatible with continued in-
ternalized or externalized stigma, i.e. persistent social
and psychological effects of having had HIV. Wilson,
Bladin and Saling report that being cured for a chronic
condition involves a challenging process of adaptation
(they refer to as the ‘burden of normality’) as the patient
emerges from the ‘sick role’ and reconstructs his or her
life activities, social relationships and self-identity [15].
Mullen talked of ‘seasons of survival’ to describe the
emotional, social and medical adaptations required by
continuing cancer survivorship over time [16]. Van Eys
argued that cure has three components (biological, psy-
chological and social), and to truly cure a patient re-
quires all three [17]. It is tempting to conceive the
biological form of cure as a necessary but not sufficient
condition for healing, wholeness, and recovery. But this
view does not represent the complex relationships be-
tween different dimensions of cure, for two reasons.
First, healing may occur even in the absence of a phys-
ical cure. A person can come to terms with an illness, be
healed in the sense of achieving a sense of ‘wholeness’,
even though not cured on the biological level. Con-
versely, a person may be physically cured of a disease,
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but there may be residual sequelae of the disease or
there may be side-effects of the means used in the
process of cure. For example, HIV may cause neuro-
logical and cardiovascular defects that may persist even
if the virus were to be eliminated. In such cases, even
when a person no longer has HIV it may be hard to
speak of him or her being ‘cured’.
Absolute and modern conceptions of cure
The distinction between sterilizing and functional HIV
cures is part of a larger distinction between absolute and
modern conceptions of cure, a distinction that pre-dates
and transcends the context of HIV. According to the
absolute conception, being cured of a health condition
means you are rid of it. It is a state of being marked by
finality. You had that health condition but now – generally
thanks to some intervention – you do not have it anymore
[18]b. The symptoms and the underlying causes of the
condition no longer exist. The understanding of cures has
likely been shaped by the idea of miraculous, religious
cures enacted by prayer, divine intervention or touch by
holy persons. Cases where the crippled (suddenly) walk or
the blind (suddenly) see are the most dramatic
transformative instances of an absolute cure. Curing
appendicitis by surgery or pneumonia by antibiotics are
secular, medical counterparts. The absolute conception
continues to shape the contemporary understanding of
cure to some extent. When an intervention does not seem
to provide a cure in the absolute sense, uncertainty often
arises as to whether we have warrant to speak about a real
cure at all. In the scientific literature and popular press,
there is a noteworthy tendency to use scare quotes (‘cure’)
when talking about anything short of an absolute cure for
HIV. The scare quotes pay tribute to the continued power
of the notion of absolute cure over the imagination.
A modern conceptualization of cure
This is to be contrasted with a more modern conception
of cure, which means that – thanks to some intervention
– chances of disease resurgence have been significantly
reduced. The definition by Easson and Russell [19],
conceiving cure as disease-free survival over long
duration, has been highly influential [19]c. The modern
conception incorporates evidence-based uncertainty of
outcome: you are cured where, on the best science
available, there is a good chance that disease remission
will continue. This conception is (for example) applied
to certain cancers, hepatitis B, Epstein-Barr virus
infection, toxoplasmosis and shingles – all instances
where a pathogen is dormant and in selected popula-
tions can be reactivated and cause disease. The concept
‘cure’ in the construct of ‘cure-rate’ is synonymous with
indefinite remission: a disease with a favorable cure rate
(say, 80%) means the likelihood of disease reoccurrence
with existing treatments is relatively low. Remission is
transformed into cure (in this sense) on the basis of data
about likely clinical outcomes over time. Where the
absolute conception of cure is categorical, the modern
conception is statistical.
Both cure conceptions currently circulate in biomedi-
cine in complex ways. Physicians continue to hesitate to
use the word ‘cure’, even when their patients have cancers
with favorable cure rates [20]. They may avoid cure
language in order to unduly raise hopes and avoid
potential litigation, suggesting that some physicians
believe their patients typically understand cure in an
absolute sense. In a qualitative study of patient/physician
interactions, Hamilton reports how while the standard
goal of Hepatitis C therapy is sustained virological
response (HCV RNA undetectable in serum for three
months post-therapy), physicians frequently continued to
speak of cure to HCV patients and invoked the absolute
conception when doing so, particularly in initial consulta-
tions [21]. A possible explanation is that patients often do
not, cannot, or do not want to understand cures for
threatening diseases in terms of probabilities. Even if the
question often cannot be answered, patients and families
may want to know if they or their loved ones will be cured
in an absolute sense. On the other hand, avoiding the
word cure has its downsides: it may reduce patient
confidence in the best intervention available, and
negatively impact adherence and self-care. In order to
anticipate issues with HIV cure, more empirical research
is needed on how the concept ‘cure’ is used and
understood in other medical domains where functional or
sterilizing cures already exist.
Epistemic issues with sterilizing and functional cures
The definitions may seem straightforward, but chal-
lenges remain. With sterilizing cure, complete elimin-
ation of all remnants of HIV from the human body is an
extremely high bar for cure. Elements of HIV may linger
in the body after a successful curative intervention. This
is currently the case with hepatitis C infection, where
residual virus – whose clinical significance is unclear –
has been detected by increasingly sensitive testing
methods. It would seem better to alter (as some have
done) the definition of sterilizing HIV cure to the elimin-
ation of replication competent proviruses in the body
[22]. This may seem like a purely virological point, but
the persistence of HIV debris (even if not ‘replication
competent’) may have psychological and social import. If
a cured person still has ‘neutralized’ HIV lingering in his
or her body, will this have any impact on his or her so-
cial identity? Will he or she no longer be considered a
person living with HIV/AIDS? We do not yet know. We
also do not currently have diagnostics that can cheaply
and readily detect the difference between replication
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competent HIV and non-replicating HIV debris. More
definitive diagnostic tests increase the likelihood of a
true sterilizing cure, but still will not guarantee it. The
situation is exacerbated by a phenomenon already evi-
dent in cancer testing: increasingly sophisticated diag-
nostic tests that reveal traces of pathological conditions
whose significance is unclear from clinical and existen-
tial perspectives. Lingering doubts that a sterilizing cure
really has been achieved– in its absolute, categorical
sense – may be very hard to shake.
The concept of functional cure is challenging in other
ways. First, a problem well known in cancer circles:
there will probably be no non-arbitrary way of determin-
ing when, after a curative intervention, the essential in-
gredients of undetectable viral load, no CD4 count loss,
lack of disease progression, negligible transmission risk
and treatment non-necessity add up to the state of being
called ‘functionally cured of HIV.’ After how many years
of HIV control without treatment (‘HIV remission’) will
we know that the patient is functionally cured?a Cancer
physicians continue to order diagnostic tests for patients
after even decades of disease remission (Miller et. al.
[13]), highlighting their own lack of confidence. On the
other hand, despite the uncertainties, being (probably)
functionally cured will likely have health, economic, so-
cial and other advantages for some patients on ART:
‘cure purgatory’ may be superior to ‘treatment hell’. But
considering the uncertainties and possible confusions
surrounding sterilizing and functional cures, why talk
about cure at all, especially now? Wouldn’t it be better
to avoid it if possible, as some have recommended in
relation to cancer? Why not replace it with (say) a state
of being called ‘long term drug free remission’? Is talking
about HIV cure at this early stage not just inaccurate or
presumptive, but in some way morally problematic?
The ethics of HIV cure talk
Why does language morally matter when it comes to
HIV cure? One reason could stem from the notion of
curative hope. Decades of clinical research have led to
the development and refinement of antiretroviral treat-
ment that has greatly benefited people living with HIV
among those who have reliable access to it. However, life
on HIV treatment has significant shortcomings. HIV-
infected individuals bear the physical brunt of acting as
host of the virus as well as the long-term effects of anti-
retroviral therapy. Many people on ART experience ser-
ious side effects, including headaches, nausea, vomiting,
rashes, pancreatitis or liver failure. Over time, HIV takes
a serious health toll even when the virus is under con-
trol, including increased risks of cardiovascular disease,
many cancers, and dementia. There are also psycho-
logical effects and economic consequences of living with
HIV and being on treatment. In short, persons living
with HIV, including those on treatment, have a number
of strong reasons to hope for a cure. Beyond wanting to
be rid of a dangerous virus or the burdens of treatment
regimes, it is also a matter of being liberated from the
social identity associated with living with HIV, the inter-
personal challenges that attach to that identity, and
release from the fear of potentially transmitting HIV to
offspring and loved ones. This is not to claim that gain-
ing a ‘HIV-positive identity’ is only negative or that the
loss of that identity would be unambiguously positive.
Individuals may affect positive life changes as a result of
becoming HIV infected, and the prospect of becoming a
person no longer living with HIV may be seen as
disadvantageous, e.g. loss of connection with the HIV
community and its history or changes to medical
benefits. Nevertheless, these complex identity concerns
are unlikely to completely dampen desires for cure.
With this powerful curative hope in the background,
how might cure language ‘do wrong’? The most obvious
way is falsehoods through unsubstantiated claims of HIV
cure. Many such claims have been made worldwide over
the last decades, and this violates ethical norms of ver-
acity and non-maleficence. A study in Tanzania suggests
that when traditional healers claim they can cure HIV,
there are negative effects on ART adherence among their
HIV-positive clients [23]. But misunderstandings are
likely to develop in subtler and less intentional ways.
Traditional media, Internet news outlets and online
social networks use language sometimes suggest a (safe,
effective, scalable, affordable) cure may have been
discovered or is just over the horizon. These claims
could arguably do psychological harm to persons living
with HIV by unduly raising and dashing hopes, and the
generation of false beliefs might have other negative
effects on behavior. Is this ‘harms due to false belief via
cure language’ scenario plausible? Some considerations
in support of this scenario include: the media’s vested
economic interest in (to a greater or lesser extent)
‘sensationalizing’ HIV cure research; that even if what is
accurately reported is a potential functional cure only
applicable to a small minority of HIV-positive persons,
the grip of the absolute conception of cure on the public
imagination may lead some to misunderstand current
HIV research advances. To what extent is this a
problem? This is another area for future social science
research.
In the short term, concern about ‘harms due to false
belief via cure language’ is likely to center on informed
consent to HIV cure research. False beliefs on the part of
prospective research participants may hinder the process
of obtaining valid informed consent in HIV cure studies.
Other forms of misconception, also involving false beliefs,
are already recognized in research. In treatment studies,
the therapeutic misconception is the well-documented
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phenomenon of research participants mistakenly believing
that they stand personally to benefit from the medical
intervention being tested [24]. In prevention studies, the
prophylactic misconception consists in research partici-
pants mistakenly believing they will be protected by the
preventive intervention being tested (such as a candidate
HIV vaccine), and possibly taking greater health risks as a
consequence. A curative misconception in HIV research
would involve HIV-positive research participants falsely
believing that they stand to be cured by the tested inter-
vention. Such beliefs could cloud the participant’s under-
standing of what the research involves, unduly influence
his or her willingness to participate in cure studies, distort
risk perception, and fuel risk behavior. As antidote to
curative misconception, some call for proof-of-concept
HIV cure studies to be called ‘experiments’ to emphasis
the risks and play down the possibility of individual bene-
fit [25]. Besides the effects of potential misconceptions,
talk of HIV cure might impact on ART treatment accept-
ance. Ingrid Katz has shown that large populations of per-
sons living with HIV already refuse antiretroviral
treatment [26]. Future research will need to focus on
whether people refuse ART because they believe a better,
‘definitive’ solution to HIV infection could be on the
horizon.
We have raised some ethical worries about the use of
the concept ‘cure’. These should not be overblown:
(1)Whether hope for HIV cure is harmful is a
complicated issue that requires future empirical
investigation and ethical analysis. Worries about
‘false hope’ may involve a misunderstanding of hope,
and underestimate the potentially positive effects of
hope as a psychological disposition and orientation
to the world. In the context of HIV research,
curative hopes are powerful desires for an outcome
believed to be good but whose fulfillment is
uncertain. If so, stimulating desires for a HIV cure
by using cure language does not seem wrong unless
false beliefs are involved in the process. Following
Horng and Grady, one should distinguish between
curative misconception, curative misestimation, and
curative optimism. If the beliefs involved in hope are
true, i.e. if HIV-positive persons know what cure
would (and would not) involve and have realistic
expectations of what current research can produce,
then the use of cure talk would not raise false hope
and destructive optimism. However, cure talk might
just be keeping hope of a better future alive, as the
dream of cure has done for HIV-positive persons
long before the recent clinical discoveries. Quantitative
and qualitative psychological research has indicated the
beneficial effects of maintaining a positive mindset.
Although further study is needed, positive attitudes
towards the future curability of HIV may help in
improving quality of life for persons living with the
virus. Whether HIV cure talk will and to what extent
lead to broader improvement in health seeking
behavior (such as regular HIV testing) remains to
be seen: beliefs about curability may hamper HIV
prevention efforts, as treatability has sometimes
done [27]. It is also possible, as Miller et. al.
suggest in the context of oncology, that patients
who believe they are cured may in fact neglect
their care, and future physicians may also regard
the continuing care of ‘cured patients’ as a lower
priority relative to other pressing health needs.
(2)The ethical question is not whether to use the concept
of HIV cure, but how, when and for what purpose.
There is something of a split between what terms
many scientists/clinicians are comfortable with
(remission, sustained virological suppression, viral
suppression off treatment) and what ‘non-experts’
would prefer to use [28]. Some argue that in clinical
contexts, ‘HIV remission’ would be a better term
than ‘HIV cure’, because remission avoids
ambiguities associated with cure, is relatively familiar
to non-experts, and sends the message to patients
that monitoring and self-care remain important [29].
Outside the clinical context, there may be legitimate
and responsible uses of the concept of ‘HIV cure’.
Advocacy groups, for example, will undoubtedly
deploy ‘cure’ when raising community awareness
and engaging the broader public. Similar to cancer
initiatives, expressions like the ‘race for a cure’ are
important means of rallying and mobilizing groups
around a common cause. The same motivational
effects might not be achieved by evoking continued
viral suppression. It is also possible – another area of
study – that explicitly and repeatedly linking ‘HIV’
and ‘cure’ will help chip away at the stigma associated
with the virus, and have other positive knock-on
effects in the HIV prevention and treatment worlds.
This too is unsure: labeling successfully treated
patients as ‘cured’ of HIV may increase the stigma of
those treated but unable to achieve a cure. Predictably,
the language of HIV cure will have intended and
unintended implications, positive and negative. It will
be important for social scientists and ethicists to
anticipate and track these as researchers get closer to
durably controlling, and hopefully eliminating, HIV.
Summary
Promising clinical developments have raised hopes for a
cure for HIV among researchers, clinicians, patients and
the general public. Efforts to gain conceptual clarity
about the meaning of ‘cure’ are not mere semantic exer-
cises, for they can elucidate the goals of HIV research
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and future clinical care. In this paper, we examine some
of the meanings of cure, as well as their assumptions
and historical precedents. We argue that attention to
language ethically matters in this context, and identify
some advantages as well as potential pitfalls of how dif-
ferent HIV/AIDS stakeholders may employ the concept
of cure. While concepts other than cure (such as remis-
sion or viral suppression) may be appropriate in clinical
contexts, use of the word cure may be justified for other
important purposes in the struggle against HIV/AIDS.
Endnotes
aAccording to the IAS definition of functional HIV
cure as lifelong control of virus in the absence of ART, it
seems functional cure can only be established at the end
of a person’s life. In this sense, not even the Berlin Pa-
tient can be said to be functionally cured yet. Definitions
of functional cure will likely change as more becomes
known about impact of curative interventions on patient
outcomes.
bAs Hillon et. al. put it: “The term ‘cure’ is defined,
inter alia, as the end of a medical condition, a substance
or procedure that ends the condition, or the state of
being healed, or cured. This is therefore an absolute
concept, and inherent in that is the permanent (and
complete) end to a specific instance of the disease” [18].
c“… cure of a disease is taken to connote that in time –
probably a decade or two after treatment – there remains
a group of disease free survivors whose annual death rate
from all causes is similar to that of a normal population
group of the same sex and age distribution” [19].
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